ALF Names Dr. Houghton as 2018 Distinguished Scientific Achievement Award Recipient
We’re proud to announce Dr. Michael Houghton, Ph.D. as the 2018 recipient of our most prestigious recognition, the Distinguished Scientific Achievement Award.
Working with Qui-Lim Choo and George Kuo at the Chiron corporation and Daniel Bradley at the CDC, Dr. Houghton identified and characterized the hepatitis C virus (HCV) in 1989 and then developed blood tests that eradicated transfusion-associated HCV infection shortly afterwards.
Along with Kangsheng Wang, Qui-Lim Choo and Amy Weiner at Chiron along with John Gerin at the NIH, Dr. Houghton identified the genome of the hepatitis D (delta) virus (HDV) in 1986 and then developed HDV blood tests.
After contributing to identifying key enzymatic steps in the HCV life-cycle during the 1990’s, his team developed a HCV vaccine candidate of proven efficacy in non-human primates which was successfully tested in phase 1 clinical trials. This HCV vaccine development now continues at the University of Alberta where he is a Professor in the Department of Medical Microbiology & Immunology and where he directs the Li Ka Shing Applied Virology Institute.
Recently, along with Amir Landi, he has also discovered new blood biomarkers of autoimmune hepatitis of clinical diagnostic utility.
Learn more about our Research Awards Program and learn more about our 2018 recipients here.How You Can Help
Share this page